|By Marketwired .||
|May 30, 2014 07:00 AM EDT||
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/30/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on June 5, 2014, at 10:30 a.m. Eastern Time.
A live webcast of the presentation will be available under Webcasts in the Investors section of www.thresholdpharm.com. A replay of the presentation will be archived on the site for 30 days.
About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in the microenvironments of most solid tumors as well as the bone marrows of some patients with hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding the potential therapeutic uses and benefits of its drug candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to: the ability of Threshold and its partner, Merck KGaA, Darmstadt, Germany, to enroll or complete clinical trials; the time and expense required to conduct such clinical trials and analyze data; issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results); risks related to Threshold's dependence on its collaborative relationship with Merck KGaA, Darmstadt, Germany; and Threshold's need for and the availability of resources to develop its drug candidates and to support Threshold's operations. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on May 1, 2014 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.
Laura Hansen, Ph.D.
Senior Director, Corporate Communications
E-mail: [email protected]
Aug. 25, 2016 09:15 PM EDT Reads: 2,184
Aug. 25, 2016 09:00 PM EDT Reads: 1,689
Aug. 25, 2016 08:45 PM EDT Reads: 1,370
Aug. 25, 2016 06:30 PM EDT Reads: 1,916
Aug. 25, 2016 05:15 PM EDT Reads: 634
Aug. 25, 2016 04:15 PM EDT Reads: 424
Aug. 25, 2016 03:30 PM EDT Reads: 1,488
Aug. 25, 2016 03:15 PM EDT Reads: 2,213
Aug. 25, 2016 02:00 PM EDT Reads: 3,546
Aug. 25, 2016 01:00 PM EDT Reads: 2,596
Aug. 25, 2016 01:00 PM EDT Reads: 3,891
Aug. 25, 2016 12:45 PM EDT Reads: 589
Aug. 25, 2016 12:15 PM EDT Reads: 3,387
Aug. 25, 2016 11:00 AM EDT Reads: 551
Aug. 25, 2016 11:00 AM EDT Reads: 1,829